Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18010007 | 0.78 | FDPS (0.53) | KCNH2FDPSALDH1A1POLBKMT2A | |
| SCHEMBL464563 | 0.78 | KCNH2 (0.43) | KCNH2TLR8FDPSALDH1A1POLB | |
| Bromide SCHEMBL6182786 | 0.76 | KCNH2 (0.40) | KCNH2TLR8ALDH1A1POLBKMT2A | |
| SCHEMBL18905838 | 0.74 | KMT2A (0.44) | KCNH2TLR8ALDH1A1POLBKMT2A | |
| SCHEMBL29295561 | 0.73 | KCNH2 (0.40) | KCNH2TLR8FDPSALDH1A1POLB | |
| SCHEMBL13861389 | 0.72 | KCNH2 (0.40) | KCNH2ALDH1A1POLBKMT2A | |
| SCHEMBL26192330 | 0.70 | KCNH2 (0.42) | KCNH2 | |
| SCHEMBL7426195 | 0.70 | SMN1; SMN2 (0.41) | KCNH2AGTR2 | |
| SCHEMBL13888854 | 0.70 | KCNH2 (0.39) | KCNH2ALDH1A1POLBKMT2A | |
| SCHEMBL11915914 | 0.69 | KCNH2 (0.50) | KCNH2FDPSALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, NOTUM, WEE1 | KCNH2 2761/4885TLR8 712/4885FDPS 231/4885 |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | ALK, NOTUM, WEE1 | KCNH2 2761/4885TLR8 712/4885FDPS 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.